Last updated: 2026-10-05 09:10:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
MDxHealth SA (MDXH) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $0.58, with a market capitalization of $54.48M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.40 to $5.33. This page covers its latest market performance, valuation, price trends and company information.
$54.48M | |
$0.57 | |
$131.70 | |
$0.40 | |
$0.58 | |
68.50K | |
5.79M | |
-- | |
$5.33 | |
$0.40 | |
-- | |
-- |
MDxHealth SA (MDXH) is trading at $0.59 in pre-market trading as of 2026-10-02 23:53:00, up 1.70% ($0.01) from the previous close of $0.58
Pre-market trading shows how investors are pricing MDXH before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, MDxHealth SA (MDXH) moved from $0.58 to $0.58, representing a gain of 0.17% ($0.00).
The stock traded between $0.52 and $0.64 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 216.29 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.7%
MDXH is currently trading at $0.58, placing it 3.7% of the way from its 52-week low of $0.40 to its 52-week high of $5.33. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
| Employees | 364 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MDxHealth SA (MDXH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.